Back to Search Start Over

Pacing burden and clinical outcomes after transcatheter aortic valve replacement-A real-world registry report.

Authors :
Natanzon SS
Fardman A
Koren-Morag N
Fefer P
Maor E
Guetta V
Segev A
Barbash I
Nof E
Beinart R
Source :
Heart rhythm [Heart Rhythm] 2022 Sep; Vol. 19 (9), pp. 1508-1515. Date of Electronic Publication: 2022 May 04.
Publication Year :
2022

Abstract

Introduction: Conflicting data exist on the prognostic significance of permanent pacemaker (PPM) implantation after transcatheter aortic valve replacement (TAVR).<br />Objective: The purpose of this study was to evaluate whether PPM implantation after TAVR is associated with adverse outcomes.<br />Methods: A retrospective analysis of a cohort comprised patients enrolled in a prospective registry between 2008 and 2019. Participants were allocated into 3 groups: patients without a prior pacemaker (n = 930 [75%]), those with previous pacemaker implantation (n = 118 [10%]), and those with pacemaker implantation after TAVR (n = 191 [15%]). The primary outcome included death and heart failure hospitalizations at 1 year. Secondary outcomes included death and heart failure hospitalizations stratified by pacing burden.<br />Results: A total of 1239 patients underwent TAVR with a median follow-up period of 2.3 years (interquartile range 1-4 years). Patients with previous and new pacemaker implantation were older (84 [80-88], 84 [80-88], and 82 [78-86] years; P = .009) and had lower baseline left ventricular ejection fraction (50% ± 15%, 55% ± 12%, and 56% ± 12%; P < .001). Patients who underwent new pacemaker implantation had higher combined outcome of death and heart failure hospitalizations (21%,12%, and 14%; P = .01). New pacemaker implantation was associated with almost twice the risk of 1-year mortality (odds ratio 1.85; 95% confidence interval 1.13-3.02; P = .014). Pacing burden, however, was not associated with the primary outcome. Furthermore, no significant difference was observed at long-term follow-up (cumulative probability to develop the primary end point at 3 years was 57% ± 2% [without PPM], 57% ± 6% [prior PPM], 54% ± 4% [new PPM]; P = .52).<br />Conclusion: Pacemaker implantation after TAVR is associated with higher 1-year adverse outcome, but this attenuates over time, suggesting that competing factors may play a role. Interestingly, pacing burden is not associated with adverse clinical course.<br /> (Copyright © 2022 Heart Rhythm Society. Published by Elsevier Inc. All rights reserved.)

Details

Language :
English
ISSN :
1556-3871
Volume :
19
Issue :
9
Database :
MEDLINE
Journal :
Heart rhythm
Publication Type :
Academic Journal
Accession number :
35525423
Full Text :
https://doi.org/10.1016/j.hrthm.2022.04.030